宣泰医药：注射用硫酸艾沙康唑获国家药监局批准上市

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of injectable Isavuconazole, which is expected to enhance its product line and competitiveness, although sales performance remains uncertain [1] Group 1: Product Approval - The company announced the approval of injectable Isavuconazole with the registration number H20256410, in a specification of 0.2g [1] - This drug is indicated for the treatment of adult invasive aspergillosis and invasive mucormycosis [1] Group 2: Market Potential - The original product is projected to generate sales of 204 million yuan in 2024 and 172 million yuan in the first half of 2025 [1] - The approval is expected to enrich the company's product portfolio and enhance its competitive position in the market [1]